News 20.08.2019 Schlieren (Zurich), Switzerland, August 20, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2019. The Company accelerated product sales in the first half of 2019, while further decreasing administrative expenses, confirming its successful transition into a full-fledged...
News 25.07.2019 Zurich, Switzerland and Rockville, MD, July 24, 2019 -- Neurimmune AG, a leading clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics and REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV®...
News 09.07.2019 Schlieren (Zurich), Switzerland, July 9, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group (ASX: PGC), a leading provider of medical...
News 09.05.2019 Zurich-Schlieren, May 9, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending March 31, 2019. “Our team is focused on delivering on our strategic priorities by advancing clinical candidates MP0250 and...
News 17.04.2019 Zurich-Schlieren, Switzerland, April 16, 2019. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority. At today’s...